表柔比星联合白蛋白紫杉醇治疗对晚期三阴性乳腺癌患者血清BRCA1及FOXA1水平的影响

Effect of epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer on serum BRCA1 and FOXA1 levels

目的探讨表柔比星联合白蛋白紫杉醇治疗对晚期三阴性乳腺癌患者血清BRCA1及FOXA1水平的影响。方法前瞻性选取2019年3月至2021年3月在同济大学附属天佑医院及复旦大学附属中山医院青浦分院肿瘤科住院治疗的晚期三阴性乳腺癌患者96例,根据随机数字法分为对照组(n=48)和治疗组(n=48);对照组患者给予静脉滴注注射用盐酸表柔比星,治疗组患者在对照组的基础上给予静脉滴注白蛋白紫杉醇。对比两组患者的临床疗效;比较两组患者的乳腺癌易感基因1(BRCA1)、叉头框蛋白(FOXA1)、血管内皮生长因子(VEGF)A、VEGFB、VEGFC、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)水平和不良反应发生率。结果治疗组患者客观缓解率和疾病控制率均高于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组患者血清BRCA1水平明显低于对照组,血清FOXA1水平明显高于对照组,差异有统计学意义(P<0.05)。血清VEGFA、VEGFB、VEGFC水平均明显低于对照组;血清炎症因子IL-6、TNF-α、CRP水平均明显低于对照组,差异有统计学意义(P<0.05)。治疗组患者神经毒性不良反应的发生率明显高于对照组(P<0.05)。结论盐酸表柔比星联合白蛋白紫杉醇治疗三阴性乳腺癌临床疗效显著,能有效降低患者血清BRCA1的表达率,提高FOXA1的表达水平,同时抑制血管内皮生长因子,并对炎症反应改善明显,且不良反应相对可控。

Objective To investigate the effect of epirubicin combined with paclitaxel on the serum levels of BRCA1 and FOXA1 in patients with triple-negative breast cancer.Methods A total of 96 patients with advanced triple-negative breast cancer who were hospitalized in the Department of Oncology,the Tianyou Hospital Affiliated to Tongji University and Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University were prospectively selected from March 2019 to March 2021.divided into the control group(n=48)and the treatment group(n=48)according to the random number method;patients in the control group were given intravenous infusion of epirubicin hydrochloride for injection,and patients in the treatment group were given intravenous infusion of albumin and paclitaxel on the basis of the control group.Compare the clinical efficacy of the two groups of patients;compare the breast cancer susceptibility gene 1(BRCA1),forkhead box protein(FOXA1),vascular endothelial growth factor A(VEGFA),vascular endothelial growth factor B(VEGFB),vascular Endothelial growth factor C(VEGFC),interleukin 6(IL-6),tumor necrosis factorα(TNF-α),C-reactive protein(CRP)levels and the incidence of adverse reactions.Results The objective remission rate and disease control rate of patients in the treatment group were higher than those in the control group(P<0.05).After treatment,the serum BRCA1 level of the treatment group was significantly lower than that of the control group(P<0.05),the serum FOXA1 level was significantly higher than that of the control group(P<0.05),and the serum VEGFA,VEGFB,and VEGFC levels were significantly lower than the control group(P<0.05).0.05;serum levels of inflammatory factors IL-6,TNF-α,and CRP were significantly lower than those of the control group(P<0.05).The incidence of neurotoxic adverse reactions in the treatment group was significantly higher than that in the control group(P<0.05).Conclusion Epirubicin combined with albumin paclitaxel has a significant clinical effect in the treatment of triple-negative breast cancer.It can effectively reduce the expression rate of serum BRCA1,increase the expression level of FOXA1,inhibit vascular endothelial growth factor,and significantly improve the inflammatory response and adverse reactions.Relatively controllable.